Clinical Trial Update: Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain [Phase 2, Phase 3]

View source ↗

Summary

ATNC05 was being investigated for atypical facial pain and related neuropathic facial pain disorders in Phase 2/Phase 3 trials. The study was withdrawn from dev…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Facial Pain
• Atypical Trigeminal Neuralgia
• Neuropathic Facial Pain
• Neuropathic Orofacial Pain
• Persistent Idiopathic Facial Pain

Drugs mentioned

• ATNC05

Snippet

Sponsor: Allodynic Therapeutics, Inc | Conditions: Atypical Facial Pain, Persistent Idiopathic Facial Pain | Phase 2, Phase 3 | Status: WITHDRAWN